Table 3. Comparison of the clinical and pathologic characteristics as well as disease outcome of advanced-stage endometrioid endometrial carcinoma cases with respect to L1CAM expression.
| All | L1CAM− | L1CAM+ | Pa | |
|---|---|---|---|---|
| Number of patients | 160 | 131 (82%) | 29 (18%) | |
| Median age (years) | 64 (range 37–93) | 64 (range 37–93) | 68 (range 47–84) | 0.40 |
| Median follow-upb (months) | 55 (range 1–227) | 58 (range 3–227) | 37 (range 1–106) | <0.01 |
| Treatment | ||||
| Lymphadenectomy | 122 (76%) | 103 (79%) | 19 (65%) | 0.13 |
| Radiotherapy | 112 (80%) | 95 (73%) | 17 (59%) | 0.14 |
| Chemotherapy | 41 (26%) | 31 (24%) | 10 (36%) | 0.23 |
| Chemoradiotherapy | 7 (5%) | 6 (5%) | 1 (4%) | 1.00 |
| FIGO stage | ||||
| II | 59 (37%) | 54 (41%) | 5 (18%) | 0.02 |
| III | 83 (52%) | 62 (47%) | 21 (72%) | 0.02 |
| IV | 18 (12%) | 15 (12%) | 3 (11%) | 1.00 |
| Grade | ||||
| 1 | 25 (16%) | 23 (18%) | 2 (7%) | 0.20 |
| 2 | 82 (51%) | 68 (52%) | 14 (48%) | |
| 3 | 53 (33%) | 40 (31%) | 13 (45%) | |
| Myometrial invasion | ||||
| <1/2 | 43 (27%) | 39 (30%) | 4 (14%) | 0.11 |
| ⩾1/2 | 117 (73%) | 92 (70%) | 25 (86%) | |
| LVSI | ||||
| No | 67 (54%) | 60 (59%) | 7 (33%) | 0.052 |
| Yes | 58 (46%) | 43 (42%) | 15 (68%) | |
| Unknown | 35 | 28 | 7 | |
| Outcome | ||||
| Residual disease | 19 (12%) | 13 (10%) | 6 (21%) | 0.12 |
| Recurrence | 41 (26%) | 28 (24%) | 13 (57%) | <0.01 |
| Locoregional | 15 (9%) | 12 (10%) | 3 (13%) | 0.71 |
| Distant | 31 (19%) | 20 (17%) | 11 (48%) | <0.01 |
| Deceased | 38 (24%) | 25 (19%) | 13 (45%) | <0.01 |
| Endometrial cancer | 26 (16%) | 16 (12%) | 10 (35%) | <0.01 |
Abbreviations: FIGO=International Federation of Gynaecology and Obstetrics; L1CAM=L1 cell adhesion molecule; LVSI=lymphovascular space invasion.
a
P-value for the Mann–Whitney U-test for continuous variables, and χ2 test for categorical variables. Bold values indicate that the differences were considered to be significant.
b
Median follow-up including deceased patients.